skip to main content

DOE PAGESDOE PAGES

Title: Centrifugal Microfluidic Platform for Rapid, Multiplexed Detection of TB and HIV Biomarkers in Whole Blood Samples

Infection with Mycobacterium Tuberculosis represents a significant threat to people with immune disorders, such as HIV-positive individuals, and can result in significant health complications or death if not diagnosed and treated early. We present a centrifugal microfluidic platform for multiplexed detection of tuberculosis and HIV biomarkers in human whole blood with minimal sample preparation and a sample-to-answer time of 30 minutes. This multiplexed assay was developed for the detection of two M.tuberculosis secreted proteins, whose secretion represents an active and ongoing infection, as well as detection of HIV p24 protein and human anti-p24 antibodies. The limit of detection for this multiplex assay is in the pg/mL range for both HIV and M.tuberculosis proteins, making this assay potentially useful in the clinical diagnosis of both HIV and Tuberculosis proteins indicative of active infection. Antigen detection for the HIV assay sensitivity was 89%, the specificity 85%. Serological detection had 100% sensitivity and specificity for the limited sample pool. The centrifugal microfluidic platform presented here offers the potential for a portable, fast and inexpensive multiplexed diagnostic device that can be used in resource-limited settings for diagnosis of TB and HIV.
Authors:
 [1] ;  [2] ;  [1] ;  [1] ;  [2] ;  [3]
  1. Univ. of Texas Medical Branch, Galveston, TX (United States)
  2. Univ. of Texas Medical Branch, Galveston, TX (United States); Sandia National Lab. (SNL-CA), Livermore, CA (United States)
  3. Sandia National Lab. (SNL-CA), Livermore, CA (United States)
Publication Date:
Report Number(s):
SAND-2015-11159J
Journal ID: ISSN 2155-9538; 616475
Grant/Contract Number:
AC04-94AL85000
Type:
Accepted Manuscript
Journal Name:
Journal of Bioengineering & Biomedical Science
Additional Journal Information:
Journal Volume: 6; Journal Issue: 2; Journal ID: ISSN 2155-9538
Research Org:
Sandia National Lab. (SNL-NM), Albuquerque, NM (United States)
Sponsoring Org:
National Institutes of Health (NIH); USDOE
Country of Publication:
United States
Language:
English
Subject:
60 APPLIED LIFE SCIENCES
OSTI Identifier:
1427202

Litvinov, Julia, Moen, Scott T., Berry, Gregory J., Loeffelholz, Michael, Singh, Anup K., and Koh, Chung Yan. Centrifugal Microfluidic Platform for Rapid, Multiplexed Detection of TB and HIV Biomarkers in Whole Blood Samples. United States: N. p., Web. doi:10.4172/2155-9538.1000230.
Litvinov, Julia, Moen, Scott T., Berry, Gregory J., Loeffelholz, Michael, Singh, Anup K., & Koh, Chung Yan. Centrifugal Microfluidic Platform for Rapid, Multiplexed Detection of TB and HIV Biomarkers in Whole Blood Samples. United States. doi:10.4172/2155-9538.1000230.
Litvinov, Julia, Moen, Scott T., Berry, Gregory J., Loeffelholz, Michael, Singh, Anup K., and Koh, Chung Yan. 2017. "Centrifugal Microfluidic Platform for Rapid, Multiplexed Detection of TB and HIV Biomarkers in Whole Blood Samples". United States. doi:10.4172/2155-9538.1000230. https://www.osti.gov/servlets/purl/1427202.
@article{osti_1427202,
title = {Centrifugal Microfluidic Platform for Rapid, Multiplexed Detection of TB and HIV Biomarkers in Whole Blood Samples},
author = {Litvinov, Julia and Moen, Scott T. and Berry, Gregory J. and Loeffelholz, Michael and Singh, Anup K. and Koh, Chung Yan},
abstractNote = {Infection with Mycobacterium Tuberculosis represents a significant threat to people with immune disorders, such as HIV-positive individuals, and can result in significant health complications or death if not diagnosed and treated early. We present a centrifugal microfluidic platform for multiplexed detection of tuberculosis and HIV biomarkers in human whole blood with minimal sample preparation and a sample-to-answer time of 30 minutes. This multiplexed assay was developed for the detection of two M.tuberculosis secreted proteins, whose secretion represents an active and ongoing infection, as well as detection of HIV p24 protein and human anti-p24 antibodies. The limit of detection for this multiplex assay is in the pg/mL range for both HIV and M.tuberculosis proteins, making this assay potentially useful in the clinical diagnosis of both HIV and Tuberculosis proteins indicative of active infection. Antigen detection for the HIV assay sensitivity was 89%, the specificity 85%. Serological detection had 100% sensitivity and specificity for the limited sample pool. The centrifugal microfluidic platform presented here offers the potential for a portable, fast and inexpensive multiplexed diagnostic device that can be used in resource-limited settings for diagnosis of TB and HIV.},
doi = {10.4172/2155-9538.1000230},
journal = {Journal of Bioengineering & Biomedical Science},
number = 2,
volume = 6,
place = {United States},
year = {2017},
month = {5}
}